BioLineRx Ltd.
TASE:BLRX Lagerbericht
Marktkapitalisierung: ₪147.6m
BioLineRx Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6 BioLineRxDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -13.3% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 102.2% pro Jahr.
Wichtige Informationen
-13.3%
Wachstumsrate der Gewinne
Biotechs Wachstum der Industrie -24.5% Wachstumsrate der Einnahmen 102.2% Eigenkapitalrendite -215.4% Netto-Marge -176.7% Letzte Ertragsaktualisierung 30 Jun 2024
Jüngste Aktualisierungen vergangener Leistungen
BioLineRx Ltd. to Report Q2, 2024 Results on Aug 15, 2024 Aug 08
BioLineRx Ltd. to Report Q1, 2024 Results on May 28, 2024 May 24
BioLineRx Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024 Mar 21
BioLineRx Ltd. to Report Q3, 2023 Results on Nov 20, 2023 Nov 14
BioLineRx Ltd. to Report Q2, 2023 Results on Aug 30, 2023 Aug 24
BioLineRx Ltd. to Report Q1, 2023 Results on May 24, 2023 May 19
Alle Updates anzeigen
Biolinerx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for Cd34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease At Ash 2024 Nov 05
BioLineRx Ltd. Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide Oct 16
New major risk - Revenue and earnings growth Aug 21
BioLineRx Ltd., Annual General Meeting, Oct 01, 2024 Aug 20
BioLineRx Ltd. to Report Q2, 2024 Results on Aug 15, 2024 Aug 08
BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease May 31
New major risk - Financial position May 30
BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology May 25
BioLineRx Ltd. to Report Q1, 2024 Results on May 28, 2024 May 24
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification May 18
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting Apr 17
Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet? Apr 02
New major risk - Share price stability Apr 01
New major risk - Revenue and earnings growth Mar 27
BioLineRx Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024 Mar 21
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production Mar 06
Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer Feb 28
BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®? Feb 16
New minor risk - Market cap size Jan 26
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease Dec 21
BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director Dec 12
New major risk - Shareholder dilution Nov 15
BioLineRx Ltd. to Report Q3, 2023 Results on Nov 20, 2023 Nov 14
New minor risk - Shareholder dilution Oct 29 BioLineRx Ltd. announced that it has received $14.6 million in funding Oct 13
New minor risk - Market cap size Oct 07
Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (Pdac) Sep 29
BioLineRx Ltd Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma Sep 12
New major risk - Financial position Aug 31
BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry? Aug 25
BioLineRx Ltd. to Report Q2, 2023 Results on Aug 30, 2023 Aug 24
BioLineRx Ltd. Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase Jul 18
BioLineRx Ltd., Annual General Meeting, Aug 07, 2023 Jun 24
BioLineRx Ltd. to Report Q1, 2023 Results on May 24, 2023 May 19
Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt? Apr 05
Rosen Law Firm Encourages Biolinerx Ltd. Investors with Losses to Secure Counsel Before Important Deadline Feb 09
Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of BioLineRx Ltd Jan 06
BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer Jan 05
BioLineRx Ltd. Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors Dec 21
Less than half of directors are independent Nov 16 BioLineRx Ltd. Announces U.S. FDA Acceptance of New Drug Application for Aphexda® (Motixafortide) in Stem Cell Mobilization
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification Nov 07
Biolinerx Ltd. Announces U.S. Commercialization Plan for Aphexda (Motixafortide) in Stem Cell Mobilization Sep 28
BioLineRx Announces Submission of New Drug Application to U.S. Food and Drug Administration for Motixafortide in Stem Cell Mobilization Sep 13
BioLineRx Ltd. to Report Q2, 2022 Results on Aug 16, 2022 Aug 12
BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer Jun 17
Is BioLineRx (TLV:BLRX) A Risky Investment? Jun 17
BioLineRx Ltd., Annual General Meeting, Jul 03, 2022 May 28
BioLineRx Ltd. to Report Q1, 2022 Results on May 11, 2022 May 06
Less than half of directors are independent Apr 27
BioLineRx Ltd. Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization Mar 05
Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way? Feb 26
BioLineRx Announces Completion of Enrollment of Phase 1/2A Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors Jan 25
BioLineRx Ltd. Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients Jan 19
Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way? Oct 17
Forecast breakeven pushed back to 2024 May 28
BioLineRx Ltd. Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients May 05
BioLineRx Ltd. to Report Fiscal Year 2020 Results on Feb 23, 2021 Feb 18
New 90-day high: ₪0.82 Feb 08
BioLineRx Ltd. Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC) Dec 18
New 90-day high: ₪0.66 Dec 15
BioLineRx Ltd. to Report Q3, 2020 Results on Nov 23, 2020 Nov 20
BioLineRx Ltd. Announces Initiation of Phase 1B Clinical Trial in Patients with Acute Respiratory Distress Syndrome Secondary to Covid-19 and Other Respiratory Viral Infections Nov 19
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization Oct 31
New 90-day low: ₪0.36 Oct 21
New 90-day low: ₪0.37 Oct 01
BioLineRx Ltd. has completed a Follow-on Equity Offering. Sep 26
BioLineRx Ltd. to Report Q2, 2020 Results on Aug 06, 2020 Aug 01
Aufschlüsselung der Einnahmen und Ausgaben
Wie BioLineRx Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie TASE:BLRX Einnahmen, Ausgaben und Erträge (USD Millions) Datum Einnahmen Umsatz Allgemeine und Verwaltungskosten F&E-Ausgaben 30 Jun 24 17 -30 35 11 31 Mar 24 12 -49 34 11 31 Dec 23 5 -61 32 13 30 Sep 23 0 -52 27 13 30 Jun 23 0 -43 20 14 31 Mar 23 0 -32 15 17 31 Dec 22 0 -25 12 18 30 Sep 22 0 -24 8 19 30 Jun 22 0 -22 7 20 31 Mar 22 0 -22 6 20 31 Dec 21 0 -27 5 19 30 Sep 21 0 -35 5 19 30 Jun 21 0 -34 5 18 31 Mar 21 0 -34 5 17 31 Dec 20 0 -30 5 18 30 Sep 20 0 -28 5 22 30 Jun 20 0 -27 5 24 31 Mar 20 0 -26 5 24 31 Dec 19 0 -25 5 23 30 Sep 19 0 -21 5 20 30 Jun 19 0 -24 5 20 31 Mar 19 0 -23 5 19 31 Dec 18 0 -23 6 20 30 Sep 18 0 -25 5 21 30 Jun 18 0 -26 6 21 31 Mar 18 0 -26 6 21 31 Dec 17 0 -24 6 20 30 Sep 17 0 -21 6 16 30 Jun 17 0 -18 6 14 31 Mar 17 0 -17 6 12 31 Dec 16 0 -16 5 11 30 Sep 16 0 -15 5 11 30 Jun 16 0 -13 5 11 31 Mar 16 0 -14 5 11 31 Dec 15 0 -14 5 11 30 Sep 15 0 -15 5 12 30 Jun 15 0 -14 5 12 31 Mar 15 0 -13 5 12 31 Dec 14 0 -11 5 12 30 Sep 14 0 -11 5 10 30 Jun 14 0 -16 5 9 31 Mar 14 0 -16 5 11
Qualität der Erträge: BLRX ist derzeit unrentabel.
Wachsende Gewinnspanne: BLRX ist derzeit unrentabel.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: BLRX ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 13.3% pro Jahr zugenommen.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von BLRX verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: BLRX ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (7.1%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: BLRX hat eine negative Eigenkapitalrendite (-215.43%), da es derzeit unrentabel ist.
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}
